Major Clinical Applications in Flow Cytometry Market
The major clinical application of technique consists of DNA and cell cycle analysis, RNA content, PNH-diagnostics, Immunophenotyping of lymphoma as well as leukaemia, Immune-deficiencies and minimal residual disease. Application of this technology for platelet function analysis and measuring the impact of cancer chemotherapy has significantly grown over the past five to six years. On the other hand, application of flow cytometry for cell function analysis, use in transfusion medicine and organ transplantation as well as hematopoietic cell therapy has kept the future of the industry robust.
Additionally, its use in microbiology helps in detecting viruses, fungi, bacteria and parasites.
Food industry is one of the key end –user of this market. The capability of the technique to detect any kind of micro-organisms even at low concentrations in less time keeps its future bright in the food sector. Besides this multiple labelling permits the detections of either diverent stages or diverent organism in same sample including food matrices.
Today, the technology has rapidly grown from basic experiment to the clinical labs. Researchers say that properties such as unique characteristics associated with cell analysis have been responsible for this growth. Among the other use of the technology cancer has emerged as the most relevant. Different applications of this technique are in use today to conduct study of cancer. This particularly consists of identifying tumour cell DNA aneuploidy and complete analysis of the proliferation of such cells.
Many academic institutions and medical colleges are coming up with flow cytometry core facilities. Located in reputed colleges or institutions these facilities offer an array of cytometry services for both external as well as internal investigations. To top it all, these facilities are backed by advanced analyzing and sorting capabilities. Some of the reputed facilities are that of UMass Medical School in Worcester, The University of Michigan Medical School, Eastern Virginia Medical School, Stony Brook School of Medicine and Tufts University School of Medicine among others.
Recently, GE Healthcare took the industry by storm when the company made its plan to collaborate with LeukoDx clear. Both the companies have joined hands to explore the possibilities for cell characterization in therapy manufacturing (cell). Commenting on their move Phil Vanek, general manager of GE’s Cell Therapy Technologies said "GE is focused on reliable, scaled-out manufacturing workflows that enable successful commercialization of cell therapies. Improved tools need to allow manufacturers to get information about the cells at every step of the process. Applying our deep knowledge and experience in cell bioprocessing to develop start-to-finish solutions, we hope to support the cell therapy industry's goal of safely and effectively treating patients suffering from devastating diseases such as cancer." In another event Bio-Techne has completed all its procedures to acquire Zephyrus Biosciences. A segment of this company provides products including fluorochrome labelled antibodies as well as kits that are used in identifying immuno-phenotypic properties cells from different tissues.
Eyeing the major developments in the market Allied Market Research has published a market research report titled “World Flow Cytometry - Market Opportunities and Forecast, 2014 - 2022.” Exclusive coverage on key market players such as Merck Millipore, Morphosys AG, Advanced Analytical Technologies, Inc. and Beckman Coulter among others forms an important part of the study. As per the study the industry was valued at $3000 million for the year 2012. Research analysts conducting the research say the sector is expected to garner about $6530 million between 2012 to 2020. They are confident that industry would register a CAGR of 30.9 percent during the forecast period.